Salute e Benessere

Tecan's Capital Markets Day highlights strategic growth drivers, groundbreaking…

Tecan's Capital Markets Day highlights strategic growth drivers, groundbreaking innovation and product launches Männedorf, Switzerland, October 22, 2024– The Tecan Group (SIX Swiss Exchange: TECN) is hosting a Capital Markets Day, including a live webcast, today in Männedorf, Switzerland, providing investors with an in-depth view of the company's solid foundations for continued growth and profitability improvements. The strategic growth drivers that enable the company to capitalize on...
Nasdaq GlobeNewswire
22/10/2024

BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of…

Global 600 patient studywillevaluateefficacyand safetyofrecombinanthumanplasmagelsolin (rhu-pGSN)formoderate-to-severeARDS.Rhu-pGSN is an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens. Endogenous levels plummet in ARDS, correlating with disease severity. NORTH BRUNSWICK, N.J., Oct.22, 2024(GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the...
Nasdaq GlobeNewswire
22/10/2024

Global Antibody-Drug Conjugate Market Set for a ~USD 26 Billion Surge by 2030 |…

Key Takeaways from the Antibody-drug Conjugate Market Report Key Takeaways from the Antibody-drug Conjugate Market Report To read more about the latest highlights related to the ADC market, get a snapshot of the key highlights entailed in the Global Antibody-drug Conjugate Market Report Antibody-drug Conjugate Overview Antibody-drug conjugates (ADCs) represent a promising class of targeted cancer therapies that combine the specificity of monoclonal antibodies with the potent...
PR Newswire
21/10/2024

/C O R R E C T I O N -- Global Health Exhibition/

During the opening ceremony, the Minister of Health, His Excellency Fahd bin Abdurrahman Al-Jalajel, highlighted the impact of health transformation in the sector, stating: "We aim to position Saudi Arabia as a hub for addressing current and future global challenges, following a unified government approach under Vision 2030. This is based on the principle of 'health in all policies' by developing regulations that encourage investment in innovation, building a healthcare system that…
PR Newswire
21/10/2024

Global Health Exhibition Opens in Riyadh With SAR 50 Billion Announced in…

He added, "Today, we are proud of the World Health Organization's recognition of Saudi Arabia's elimination of trans fats from food products, placing the Kingdom at the forefront of countries receiving this distinction. Additionally, the WHO has announced that Saudi Arabia, represented by the Saudi Food and Drug Authority, is the first country in the region to achieve the highest 'maturity level 4' in the regulation of medicines and vaccines." He added, "Today, we are proud of the…
PR Newswire
21/10/2024

Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in…

Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentumDIAMOND program committees expanded with globally renowned retina expertsIf approved, OCS-01 has the potential to transform the treatment paradigm as the first topical eye drop to treat DMEOculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces the acceleration...
Nasdaq GlobeNewswire
21/10/2024

Antibody-Drug Conjugates Market to Grow at 28.4% CAGR from 2024 to 2029

ADCs are at the forefront of precision medicine, offering high specificity for cancer cells while minimizing toxicity. With 13 commercially available products globally and more than 200 in clinical trials, ADC development has become one of the most attractive classes of biological drugs. Significant investment in research and development by pharmaceutical and biotech companies and the increasing number of ADCs in clinical trials are important drivers of the ADC market. ADCs are at the…
PR Newswire
21/10/2024

Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER…

PRESS RELEASE REGULATED INFORMATION 21 October 2024, 06:00 p.m. CESTSEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARESGhent, Belgium, 21 October 2024 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that in the context of a subscription to new shares by certain members of the Company's management team upon...
Nasdaq GlobeNewswire
21/10/2024

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

Saint-Herblain (France), October 21, 2024–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today that members of its senior leadership team will present datasets on the world's first and only approved chikungunya vaccine, IXCHIQ ®, at several leading scientific conferences during the fourth quarter of 2024.At theInternational Society of VaccinesAnnual Congresstaking place in Seoul, South Korea, Valneva will present on the two-year antibody...
Nasdaq GlobeNewswire
21/10/2024

Osteotec appointed as Novastep's exclusive distribution agent for the UK…

This strategic collaboration enhances Osteotec's comprehensive portfolio, enabling surgeons to access Novastep's portfolio of implants designed to address a wide range of conditions, from trauma to pathological and congenital deformities. The addition further strengthens Osteotec's commitment to delivering solutions that support better clinical outcomes. Based in Rennes,France, Novastep is a recognised leader in the development of innovative, minimally invasive surgical (MIS)...
PR Newswire
21/10/2024

Responsibility statement for first half year of 2024

Please find attached the first half 2024 financial report including the Responsibility Statement.***** For further information, please contact: Alexander Karlsen CFO +47 97 05 36 21 [email protected] information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Vistin Pharma ASA Q2 report 2024
Nasdaq GlobeNewswire
21/10/2024

Surgical N95 Respirators Market Size to Grow USD 4018.3 Million by 2030 at a…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-1E8590/Global_Surgical_N95_Respirators_Market Get Free Sample : https://reports.valuates.com/request/sample/QYRE-Auto-1E8590/Global_Surgical_N95_Respirators_Market Major Factors Driving the Growth of Surgical N95 Respirators Market The Surgical N95 Respirators Market is expected to witness robust growth in the coming years due to the increasing prevalence of airborne diseases and heightened demand for...
PR Newswire
21/10/2024

Moleac Announces PT Ferron Par Pharmaceuticals as New Exclusive Partner in…

This partnership marks a crucial milestone in our mission to widen access to our groundbreaking products, supporting healthcare professionals in enhancing outcomes for patients recovering from stroke, traumatic brain injuries, and neurodegenerative diseases. This partnership marks a crucial milestone in our mission to widen access to our groundbreaking products, supporting healthcare professionals in enhancing outcomes for patients recovering from stroke, traumatic brain injuries, and...
PR Newswire
21/10/2024

Bioprocessing Market Size Worth $72.55 Billion, Globally, by 2031 - Exclusive…

Browse Detailed Report: https://www.theinsightpartners.com/reports/bioprocessing-market Browse Detailed Report: https://www.theinsightpartners.com/reports/bioprocessing-market Competitive Strategy and Development Download Sample Report:https://www.theinsightpartners.com/sample/TIPRE00039016/ Global Headlines on Bioprocessing Identify the Key Trends Affecting This Market - Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00039016/ Overview of...
PR Newswire
21/10/2024

Coloplast A/S - FY 2023/24 Earnings Release - Invitation for conference call on…

Tuesday, 5 November 2024 at 11.00 – 12.00 CETIn connection with the publication of Coloplast's interim financial results for FY 2023/24 the company will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast's website approximately 1 hour before the conference call. Please note that the webcast of the conference call will be available during and after the event.Coloplast will be...
Nasdaq GlobeNewswire
21/10/2024

New employee-elected board member

Company announcement No. 42Anne Breum, one of the employee-elected members of the Board of Directors of Novozymes A/S, part of Novonesis Group (the “Company”), has decided to step down as a board member. The first alternate, Lena Bech Holskov (Safety Adviser, OHS) has replaced Anne Breum as employee-elected board member of the Company for the remaining period of the current four-year election term ending following the annual general meeting of the Company to be held on April 3, 2025...
Nasdaq GlobeNewswire
21/10/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 21 October 2024– On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.Under the...
Nasdaq GlobeNewswire
21/10/2024

Buyback of Class B shares in Essity during week 42, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
21/10/2024

Global Health Exhibition Launches in Riyadh, Witnessing SAR 50 Billion in…

Al-Jalajel also highlighted the expansion of the Saudi Board Program, which now offers 170 healthcare specialties, with 3,000 international practitioners enrolled. Speaking on investment opportunities, he said: "Investment in the healthcare sector continues to grow, with Saudi Arabia leading the region in healthcare investments. The largest public offering in the Saudi market this year was for Dr. Faqih Healthcare Group, preceded by the IPO of Dr. Sulaiman Al Habib Group, which was among…
PR Newswire
21/10/2024

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial…

Daix (France), Long Island City (New York, United States), October 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“ MASH ”), also known as non-alcoholic steatohepatitis (“ NASH ”), today announced that the results of the Phase 2, LEGEND, evaluating lanifibranor in...
Nasdaq GlobeNewswire
21/10/2024

Cizzle Biotechnology announces North American licensing deal to launch…

Whilst the renowned Moffitt Cancer Center in Florida conducts a major clinical evaluation of the CIZ1B biomarker lung cancer test in a real-world, high-volume clinical environment, the target is to secure CLIA accreditation for the test by the end of 2024, with a full product launch in North America planned for April 2025. Whilst the renowned Moffitt Cancer Center inFloridaconducts a major clinical evaluation of the CIZ1B biomarker lung cancer test in a real-world, high-volume clinical...
PR Newswire
21/10/2024

KFSHRC Successfully Conducts Pharmacogenetic Analysis for Over 1,500 Patients

RIYADH, Saudi Arabia, Oct.21, 2024(GLOBE NEWSWIRE) -- Since its launch in early September last year, King Faisal Specialist Hospital & Research Centre (KFSHRC) has successfully conducted pharmacogenetic analysis for over 1,500 patients, as a novel medical approach, focusing on tailoring medications to patient's DNA (genetic code), allowing for precise predictions of drug efficacy and the selection of the most effective and safest treatments. This represents a significant shift from...
Nasdaq GlobeNewswire
21/10/2024

BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on…

MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2024 on Monday, November 4, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please...
Nasdaq GlobeNewswire
21/10/2024

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating…

Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW171 in treatment of ovarian cancer, non-small cell lung cancer (NSCLC), and other mesothelin (MSLN) expressing cancers VANCOUVER, British Columbia, Oct.21, 2024(GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the...
Nasdaq GlobeNewswire
21/10/2024
Altri  Comunicati